Compare Roundhill Magnificent Seven ETF (MAGS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Sanofi SA — how do they compare? Roundhill Magnificent Seven ETF trades at $73.72 (market cap $5.78B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 16.5× Roundhill Magnificent Seven ETF's market cap, and Sanofi SA pays a 6.01% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Sanofi SA for 94 Days on average.
| MAGS | SNY | |
|---|---|---|
Market Cap | $5.78B | $95.18B |
Volume | 4,410,665 | 2,995,646 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $52.34 |
52-Week Low | $55.39 | $39.51 |
Typical Hold Time | 36 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $73.66, showing minimal daily movement with a slight 0.04% decline. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF provides equal-weighted exposure to the Magnificent Seven mega-cap tech stocks, though recent performance has trailed broader market indexes with modest 2% year-to-date gains.
The outlook remains cautiously optimistic given the ETF's concentrated tech exposure and AI growth themes. Key risks include market concentration, valuation concerns, and potential regulatory scrutiny. Wall Street sentiment appears mixed as investors weigh long-term AI potential against near-term performance challenges.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
